Form 4: Liquidia CMO Sells Shares for Tax Obligations

Liquidia Corp's Chief Medical Officer, Rajeev Saggar, sold 5,327 shares of common stock at $23.41 to cover tax liabilities from vested equity awards.

Summary

• Rajeev Saggar, Chief Medical Officer of Liquidia Corp (LQDA), acquired 3,530 shares of common stock on October 10, 2025, through the conversion of Performance Stock Units (PSUs).
• Following this acquisition, beneficial ownership increased to 253,257 shares.
• On October 13, 2025, Mr. Saggar sold 5,327 shares of common stock at a price of $23.41 per share.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
• The purpose of the sale was to cover taxes associated with the settlement of previously granted Restricted Stock Units (RSUs) and PSUs from January 11, 2023, and January 11, 2024.
• After the sale, Mr. Saggar's direct beneficial ownership stands at 247,930 shares of common stock.
• Beneficial ownership includes 26,041 unvested RSUs from a January 11, 2023 grant, 31,777 unvested RSUs from a January 11, 2024 grant, 71,780 unvested RSUs from a January 11, 2025 grant, and 7,139 shares acquired under the Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale to cover tax obligations from vested equity awards, executed under a pre-arranged 10b5-1 plan, which is generally considered neutral in terms of company sentiment.

Positives

• The conversion of Performance Stock Units (PSUs) into common stock indicates the vesting of equity awards, which is a positive for the executive.
• The transaction was executed under a pre-arranged Rule 10b5-1 plan, suggesting a planned, non-discretionary sale rather than an opportunistic one.

Negatives

• An insider disposition of 5,327 shares, even for tax purposes, reduces the executive's direct ownership in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction represents a routine insider trading activity, common across all industries, where executives sell a portion of their vested equity awards to cover tax liabilities. It does not reflect specific industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related insider sale, not indicative of a change in company fundamentals or management's confidence.
• Employees: No direct impact mentioned beyond the executive's compensation structure.

Next Steps

• Continued vesting of remaining unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) according to their respective schedules.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of shares by a Chief Medical Officer to cover tax obligations arising from vested equity awards. Such transactions are common and do not typically signal a change in the company's fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Liquidia Corp, LQDA, Form 4, Insider Transaction, Rajeev Saggar, Chief Medical Officer, Equity Awards, RSU, PSU, 10b5-1 Plan, Stock Sale, Tax Obligations